Pilot trial of Aspirin versus Ticagrelor in Congestive Heart Failure
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs Ticagrelor (Primary) ; Aspirin
- Indications Embolism and thrombosis; Heart failure
- Focus Biomarker; Pharmacodynamics
- Acronyms PATCH
- 08 Jun 2016 Status changed from discontinued to withdrawn prior to enrolment.
- 08 Sep 2014 Status changed from not yet recruiting to discontinued as reported by Australian New Zealand Clinical Trials Registry record.
- 23 Aug 2013 New trial record